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Clinical trialTo evaluate the role of V3-speciﬁc IgG antibodies (Abs) in the RV144 clinical HIV vaccine trial, which reduced
HIV-1 infection by 31.2%, the anti-V3 Ab response was assessed. Vaccinees' V3 Abs were highly cross-reactive
with cyclic V3 peptides (cV3s) from diverse virus subtypes. Sieve analysis of CRF01_AE breakthrough viruses
from 43 vaccine- and 66 placebo-recipients demonstrated an estimated vaccine efﬁcacy of 85% against viruses
with amino acids mismatching the vaccine at V3 site 317 (p= 0.004) and 52% against viruses matching the vac-
cine at V3 site 307 (p = 0.004). This analysis was supported by data showing that vaccinees' plasma Abs were
less reactive with I307 when replaced with residues found more often in vaccinees' breakthrough viruses. Simul-
taneously, viruses with mutations at F317 were less infectious, possibly due to the contribution of F317 to optimal
formation of the V3 hydrophobic core. These data suggest that RV144-induced V3-speciﬁc Abs imposed immune
pressure on infecting viruses and inform efforts to design an HIV vaccine.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The vaccine tested in the RV144 Thai clinical trial provided modest
protection in healthy heterosexual individuals against HIV-1 infection.4N, New York, NY 10010, USA.
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. This is an open access article underTo date this is the only HIV clinical trial to demonstrate vaccine efﬁcacy
(VE), albeit at a level of 31.2% (Rerks-Ngarm et al., 2009). A case–control
study designed to identify immune correlates of reduced infection risk
demonstrated that high levels of antibodies (Abs) directed against the
V1V2 region of the virus gp120 envelope glycoprotein were associated
with a decreased risk of HIV-1 infection, while high levels of Env-
speciﬁc plasma IgA were associated with an increased risk (Haynes
et al., 2012). The V1V2 vaccine-induced Abs were shown to be broadly
reactive with the V2 region of multiple subtypes despite immunization
with immunogens from only subtypes B and CRF01_AE (Zolla-Pazner
et al., 2013, 2014). Genetic studies that compared the V1V2 region of vi-
ruses infecting placebo and vaccine recipients identiﬁed two positions
in V2, 169 and 181, that distinguished viruses from vaccine recipients,
resulting in VEs of 48% and 78%, respectively (Rolland et al., 2012).
This sieve analysis complemented the ﬁnding of an association between
high V1V2-binding Abs and reduced HIV-1 acquisition, and providedthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Sequences of cyclic V3 peptides used to analyze cross-reactivity and speciﬁcity of the
RV144-induced antibody response directed against V3.a
Cyclic V3 Peptide (subtype 
or amino acid variant) Sequence
b
MN (B) CTRPNYNKRKRIHIGPGRAFYTTKNIIGTIRQAHC
BaL (B) CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC
92TH023 (CRF01_AE) CTRPSNNTRTSINIGPGQVFYRTGDIIGDIRKAYC
A244 (CRF01_AE) CTRPSNNTRTSITIGPGQVFYRTGDIIGDIRKAYC
Consensus (C) CTRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAHC
1086 (C) CTRPNNNTRKSIRIGPGQTFYATGDIIGNIRQAHC
Consensus (A) CTRPNNNTRKSIRIGPGQAFYATGDIIGDIRQAHC
Consensus (CRF02_AG) CTRPNNNTRKSVRIGPGQTFYATGDIIGDIRQAHC
BaL (I307V) CTRPNNNTRKSVHIGPGRAFYTTGEIIGDIRQAHC
BaL (I307M) CTRPNNNTRKSMHIGPGRAFYTTGEIIGDIRQAHC
BaL (I307T) CTRPNNNTRKSTHIGPGRAFYTTGEIIGDIRQAHC
BaL (I307A) CTRPNNNTRKSAHIGPGRAFYTTGEIIGDIRQAHC
A244 (I307V) CTRPSNNTRTSVTIGPGQVFYRTGDIIGDIRKAYC
A244 (I307M) CTRPSNNTRTSMTIGPGQVFYRTGDIIGDIRKAYC
A244 (I307T) CTRPSNNTRTSTTIGPGQVFYRTGDIIGDIRKAYC
A244 (I307A) CTRPSNNTRTSATIGPGQVFYRTGDIIGDIRKAYC
CRF01_AE (Linear) SNNTRTSITIGPGQVFYRTGD
b Cyclic and linear peptides each have a biotin residue and a three glycine linker
covalently bound to the N-terminal cysteine.
a Positions 307 and 317 are underlined and substitute amino acids are shown in bold.
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had a role in the reduced rate of infection associated with the RV144
vaccine regimen (Liao et al., 2013; Liu et al., 2013; Zolla-Pazner et al.,
2013; Pollara et al., 2014; Yates et al., 2014).
Additional analyses showed that plasma Abs from RV144 vaccinees
reactive in a microarray to a linear V3 peptide from CRF01_AE were
also an inverse correlate of infection risk, but only in vaccine recipients
who had lower levels of Env-speciﬁc plasma IgA and aggregate neutral-
izing Ab activity (Gottardo et al., 2013), and V3-speciﬁc Abs fromRV144
vaccinees were shown to capture infectious virions, including the vac-
cine strain CM244 (Liu et al., 2013). These and previous data
(Karasavvas et al., 2012) generated the hypothesis that IgG Abs to epi-
topes in both the V2 and V3 regions of gp120 are part of a complex in-
terplay of immune responses that contributed to the reduced rate of
infection in RV144 participants, and suggested that further delineation
of additional elements of the V3 Ab responsemight reveal important in-
formation about the factors involved in blocking HIV infection.
Extensive data in the literature support a possible protective role for
Abs directed against the crownof theV3 loop. The proof of principle that
humanmonoclonal Abs (mAbs) speciﬁc for the V3 loop could reactwith
and neutralize many strains of HIV, including lab-adapted and primary
isolates from several HIV subtypes, was established 20 years ago
(Gorny et al., 1992, 1993; Conley et al., 1994). Cross-clade neutralization
by V3 Abs has now been conﬁrmed (Gorny et al., 1997, 2002; Corti et al.,
2010; Hioe et al., 2010; Mouquet et al., 2011; Klein et al., 2012), and V3
mAbs have been shown to provide sterilizing immunity by passive im-
munization in various animal models (Emini et al., 1992; Safrit et al.,
1993; Andrus et al., 1998; Eda et al., 2006;Watkins et al., 2011). Further-
more, the V3 region is one of themost immunogenic epitopes in the en-
velope, inducing glycan-independent Abs directed at the crown of the
V3 loop in N90% of HIV-infected individuals (Gorny et al., 1997, 2002;
Zolla-Pazner, 2005). These Abs show cross-clade immunochemical
and neutralizing activity (Gorny et al., 2004; Corti et al., 2010; Hioe
et al., 2010; Mouquet et al., 2011) despite the fact that their CDR H3 re-
gions are comparable to the average length of this segment (mean of 16
amino acids), and their VH regions differ from germline by a mean of
only 8.6% (Andrabi et al., 2013). A second type of V3-directed Ab is
glycan-dependent, speciﬁc for the base of V3 and the adjacent glycan
in C4; these Abs are extremely broadly reactive and potent, but are in-
duced in only a small percentage of infected individuals, and their
heavy chains are extensively mutated from germline (27–34%), reﬂec-
tive of somatic hypermutationwhich requires several years of exposure
to antigen (Pejchal et al., 2011;Walker et al., 2011;Mascola andHaynes,
2013).
An early indication that V3 bears conserved structural elements
allowing the broad cross-reactivity of V3 Abs directed to the crown of
the V3 loop came from data showing that V3 participates in the binding
of gp120 to the cell surface coreceptors CCR5 or CXCR4 and in determin-
ing virus tropism (Shioda et al., 1991, 1992; Trkola et al., 1996; Hill et al.,
1997). Subsequently, extensive crystallographic studies of V3 mAbs in
complex with V3 peptides revealed a generic β-strand/turn/β-strand
structure for the V3 crown encompassing a hydrophobic core (often
composed of the highly conserved amino acids I307, I309 and F317) and
a hydrophilic face (including amino acids at positions 306, 308 and
316 which are positions displaying considerable variation) (Almond
et al., 2010; Jiang et al., 2010; Zolla-Pazner and Cardozo, 2010).
In order to examine the V3 Abs induced by the RV144 vaccine regi-
men, the immunochemical characteristics of V3-speciﬁc Abs in vaccine
recipientswere studied. Simultaneously, V3 sequence variation in virus-
es infecting vaccine and placebo recipients were compared and key V3
residues were analyzed to understand their contribution to optimal V3
structure and function. The results of these analyses complement one
another, suggesting that V3 Abs played a role in reducing the infection
rate and exerting immune pressure on the breakthrough viruses by
selecting against viruses with the consensus Ile at position 307 and
selecting for viruses that retain Phe at position 317.2. Materials and Methods
2.1. Ethics Statement
The RV144 clinical vaccine trial was registered with ClincialTrials.gov
and assigned a registration number of NCT00223080. It was approved by
all relevant institutional and governmental committees, and the protocol
of the trial was described in (Rerks-Ngarm et al., 2009). Speciﬁcally, the
institutional review boards of the Thai Ministry of Public Health Ethics
Committee, the Royal Thai ArmyMedical Department, Ethics Committee
of the Faculty of Tropical Medicine, Mahidol University, and the US Sur-
geon General's Human Subjects Research Review Board approved the
protocol and attendant immune correlates work. All subjects provided
written informed consent and passed a test of understanding as previ-
ously described (Rerks-Ngarmet al., 2009). Brieﬂy, RV144was a commu-
nity-based, randomized, multicenter, double-blind, placebo-controlled
vaccine efﬁcacy trial consisting of four injections of a recombinant
canarypox vector vaccine (ALVAC-HIV [vCP1521]) given at 0, 1, 3, and
6 months, and two injections of recombinant gp120 subunits (AIDSVAX
B/E®) given at months 3 and 6. The vaccine and placebo injections were
administered to 16,402 healthymen andwomen between the ages of 18
and 30 years in Thailand.2.2. Plasma and Peptides Used
The plasma set used here consisted of plasma from 20 placebo recip-
ients and 40 vaccine recipients participating in the RV144 trial who
were HIV seronegative at the end of the study period; blood specimens
had been collected at weeks 0, 26 and 52.
Cyclic V3 peptides (cV3) were synthesized commercially (Biopeptide
Co., San Diego, CA) using the sequences of viruses from subtypes A, B, C,
CRF01_AE and CRF02_AG (Table 1). These peptides had a biotin residue
and a three glycine linker covalently bound to the N-terminal cysteine.
In addition, a linear V3 peptide, biotin-GGGSNNTRTSITIGPGQVFYRTGD,
representing the consensus sequence of CRF01_AE was synthesized
(Biopeptide Co.) since IgG to a linear peptidewith this V3 sequence tested
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0.54 per SD increase, p = 0.0042) (Gottardo et al., 2013).2.3. ELISA Assay
StreptaWell plates (Roche) were coated with 1 μg/ml biotinylated
cV3s for 1.5 h at 37°C and then washed six times with phosphate-
buffered saline containing 0.05% Tween-20, pH 7.4, before incubation
for 1.5 h at 37°C with RV144 plasma diluted 1:100 in RPMI medium
containing 15% fetal bovine serum. The plates were washed six times,
and alkaline phosphatase-conjugated goat anti-human IgG (1:2000)
was added for 1.5 h at 37°C. After washing, 10% diethanolamine sub-
strate was added for 30 min to develop color, and the plates were
read at Å405 nm. At each step, every well contained 50 μl; specimens
were run in duplicate in each experiment, and two or three experiments
were performed with each plasma/peptide combination.2.4. Site-directed Mutagenesis, Production of Pseudoviruses in 293T Cells,
and Infectivity Assays
Point mutations were introduced in the V3 region of plasmids
TH023.06 and CM244OR.01 which were kindly supplied by Dr. Agnes-
Laurence Chenine at the H. M. Jackson Foundation using the QuikChange
II XL Site-DirectedMutagenesis Kit (Stratagene, La Jolla, CA, USA), accord-
ing to the manufacturer's instructions. All mutant constructs were se-
quenced to conﬁrm the correct amino acid change. Wild type or mutant
plasmids were used to co-transfect 293T human embryonic kidney cells
(ATCC,Manassas, VA, USA)with a pSGdelta_env backbone plasmid at op-
timal backbone to envelope ratios, using Fugene HD (Roche, Manheim,
Germany) according to themanufacturer's protocol. After 48–72h, super-
natants containing the secreted mutant or wild type pseudoviruses were
harvested, ﬁltered, aliquoted and stored at−80°C. Infectivity was tested
by titration of supernatants using TZM.bl indicator cells (JC53BL-13, ob-
tained from the NIH AIDS Research and Reference Reagent Program).
Brieﬂy, ﬁve-fold serial dilutions of env-pseudotyped virus stocks were
incubated for 48 h in quadruplicate with TZM.bl cells and assayed for
luc reporter gene activity using Bright-Glo (Promega) under standard
TZM.bl assay conditions.2.5. Sequence Analysis
Viral genomes were sequenced following endpoint-dilution PCR of
viral RNA from plasma specimens collected at the time of HIV-1 diagno-
sis (GenBank accession numbers JX446645–JX448316). Details of the
sequencing of the viruses were previously described, and sequences
from the 109 independent infections with CRF01_AE viruses were
used in the sieve analysis (Rolland et al., 2012).2.6. Sieve Analysis
Differential VE by genotype was assessed as previously described
(Lunn and McNeil, 1995; Gilbert, 2000) using one representative se-
quence per individual, i.e., the HIV-1 genomic sequence that is the clos-
est to the consensus sequence derived from all the sequences obtained
from that individual (Rolland et al., 2012).2.7. Covariation
Associations between residues were assessed using the Kullback–
Leibler divergence covariation and differential covariation tests (Gilbert
et al., 2005) and two Bayesian graphical methods were used which are
phylogenetic comparativemethods that explicitlymodel the evolutionary
history of the sequences (Poon et al., 2007; Carlson et al., 2008).2.8. Vaccine Efﬁcacy
Genotype-speciﬁc VE was assessed with the Cox proportional
hazards model and score test as described by Prentice et al. (1978),
and genotype-speciﬁc VE was calculated based on one representative
sequence per individual. Negative VE values are shown in symmetrized
form (as the negative of the VE value calculated with vaccine and place-
bo groups interchanged).
2.9. Statistical Analyses
Themean difference between pairs of cV3 antigens was tested using
a paired t-test of the null hypothesis that the true mean difference is
zero. Adjusted P-values are based on theHolm FWER adjustment proce-
dure (Holm, 1979).
2.10. Funding Sources
This work was supported in part by contracts between the NYU
School of Medicine and the Narrows Institute of the VA Harbor
Healthcare System with the Military HIV Research Program (Contracts
692526 and 793356), through funds from the Department of Veterans
Affairs, VeteransHealth Administration, and by grants from theNational
Institutes of Health (P01 AI100151 [SZP and XPK] and R01 HL59725
[SZP]). The work was also supported by an Interagency Agreement
Y1-AI-2642-12 between the U.S. Army Medical Research and Material
Command (USAMRMC) and the National Institutes of Allergy and Infec-
tious Diseases and by a cooperative agreement (W81XWH-07-2-0067)
between the Henry M. Jackson Foundation for the Advancement of Mil-
itary Medicine, Inc., and the U.S. Department of Defense. The content is
solely the responsibility of the authors and does not necessarily repre-
sent the ofﬁcial views of the National Institutes of Health, the Depart-
ment of Defense, or the Department of Veterans Affairs who did not
participate in the interpretation of data, the decision to submit theman-
uscript for publication, or the writing of this paper.
3. Results
3.1. Assessment of the Cross-reactivity and Longevity of V3 Abs in Plasma of
RV144 Vaccinees
A plasma set from the previously described RV144 vaccine trial
(Rerks-Ngarm et al., 2009) was used for these studies. The plasma
were derived from study participants and consisted of plasma from 20
placebo recipients and 40 vaccine recipientswhowereHIV seronegative
at the end of the study period; the specimens used had been collected at
weeks 0, 26 (two weeks after the last immunization) and 52.
Cyclic V3 peptides representing this region from subtypes A, B and C
and fromCRF01_AE (AE) and CRF02_AG (AG) (Table 1)were used to as-
sess the cross-reactivity of V3 Abs in the plasma of the panel of RV144
vaccine and placebo recipients. All specimens were tested at a dilution
of 1:100. The response rate to cV3s by vaccinees' specimens at week
26 ranged from 87.5% (35/40) for cV3AE(92TH023), to 95% (38/40) for
cV3AE(244) and to 100% for consensus A, AG, and C, and subtype B strains
MN and BaL cV3s (Table 2). Thus, like the V2 Ab response (Zolla-Pazner
et al., 2013, 2014), the V3 Ab response generated by the RV144
immunization regimenwas highly cross-reactive. The strongest response
was detected with the cV3 peptide homologous to that of the gp120MN
protein boost, while the weakest responses were detected to the cV3s
CRF01_AE (A244 and 92TH023) despite the fact that gp120AE(A244) was
also used as a gp120 protein boost (Fig. 1). The data were also analyzed
to determine how well the responses to various cV3s correlated with
one another. These data, shown in Supplementary data Fig. S1, indicate
that Spearman correlation coefﬁcients range from 0.48 to 0.98 for the
wild type cV3s. For example, a correlation of 0.80 was achieved for reac-
tivity with cV392TH02 and cV3Consensus A and a correlation of 0.94 was
Table 2
Longitudinal V3 antibody response rates in placebo and vaccine recipients.a
cV3
Week Week Week Week Week Week 
0 26 52 0 26 52
MN 0 0 0 2.5 100 55
BaL 0 0 0 5 100 20
Cons A 0 0 0 5 100 35
C 1086 0 0 0 5 100 32.5
Cons AG 0 0 0 5 100 25
Cons C 0 0 0 5 100 25
92TH023 5 5 5 0 87.5 7.5
A244 0 0 0 5 95 15
a Light gray = placebo recipients (n = 20); dark gray = vaccinees (n = 40). A posi-
tive response is deﬁned as an optical density greater than a peptide-speciﬁc cut-off, calcu-
lated as three standard deviations above the mean of the week 0 readings.
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sponses correlated across clades. These data, generated with cV3s, con-
ﬁrm previously reported microarray data with linear V3 peptides
(Gottardo et al., 2013) and indicate that the V3-speciﬁc Abs were prefer-
entially induced by gp120MN. There were statistically signiﬁcant differ-
ences in reactivities between 25 of the 28 pairs of the cV3 peptides
when the results with the week 26 plasma were analyzed (Table S1).
To determine the longevity of theV3Ab response, V3 Ab reactivity to
the same eight cV3s was measured with plasma drawn at week 52. The
reactivity decreased markedly over time in all specimens from vacci-
nees, but notably, many specimens continued to show positive reactiv-
ity 28 weeks after the last boost. The highest response rate in week 52
specimens when tested at a dilution of 1:100 was 55% (22/40) vs.
cV3B(MN) compared to 100% at week 26, while only 7.5% (3/40) of spec-
imens from week 52 remained positive vs. cV3AE(92TH023) compared to
87.5% at week 26 (Table 2).
3.2. Sieve Analysis of Viruses Infecting Placebo and Vaccine Recipients
A comprehensive sieve analysis of breakthrough infections in RV144
has been performed to test for evidence of vaccine-induced immuneFig. 1. ELISA reactivitywith cyclic V3peptides of RV144 vaccinees' plasma (n=40) drawn
at week 26 (two weeks after the last immunization). The y-axis shows optical density
readings at 405 nm for each plasma specimen against a given cyclic V3 peptide (identiﬁed
on the x-axis). Plasma from placebo recipients were non-reactive and are not shown. All
the cyclic V3 peptides were tested in two to three experiments, with two replicates in
each experiment; a representative experiment is shown. As shown in Table S1, each
group was signiﬁcantly different from one another (Holm adjusted p-values less than
0.05) except for Conc C vs. A244 (p = 0.086), Conc C vs. 92TH023 (p = 0.16) and
92TH023 vs. A244 (p = 0.16).pressure across the entire HIV-1 proteome (Edlefsen et al., in press) as
opposed to the original sieve analysis which only interrogated V1V2
sites (Rolland et al., 2012). In the former Edlefsen paper, site scanning
methods tested all variable positions across the entire HIV-1 proteome
to identify sites where VE was signiﬁcantly different (p b 0.05) against
two genotypes of HIV-1 deﬁned by match or mismatch of the amino
acid (AA) to the AA at that site in the vaccine; the data relevant to V3
position 317, described here, are part of this analysis in that the differen-
tial VE at site 317 was considered signiﬁcant (p = 0.04). The data
pertaining to V3 position 307 was not included in the Edlefsen paper
since the p-value of the differential VE at site 307 was 0.065.
The consensus residues among the viruses from both the 43 infected
vaccinees and 66 infected placebo recipients were isoleucine at position
307 (I307), and phenylalanine at position 317 (F317) (Fig. 2). Site 307was
more frequently mutated in sequences from vaccine recipients — in 51%Fig. 2. Fraction of viruses from vaccinees and placebo recipients with designated residues
at V3 position 307 and V2 position 169 (A), and with designated residues at V3 position
317 and V2 position 181 (B). The vaccine immunogen amino acid is represented by the
bottom-most bar in each plot. For all positions except Env 169, the amino acid was the
same in all three immunogen sequences; at Env 169 theMN immunogenAA (methionine)
was not found in any subject's breakthrough sequence so it is not depicted.
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was more conserved in sequences from vaccine recipients — in 95% of
vaccinees compared to 71% of placebo recipients. We veriﬁed that the
vaccine status was associated with mutations at site 317 independent
of the tree topology (p = 0.022), and similarly for the I307X signature
(p = 0.053) (data not shown). A covariation analysis was performed
to assess the relationship between sites 307 and 317; statistical signiﬁ-
cance was not reached for linkage between sites 307 and 317.
Overall, VE was estimated at 31% in the RV144 trial; here we looked
at VE as a function of the HIV-1 genotype at sites 307 and 317. Vaccine
efﬁcacy (VE) was increased to 52% (CI: 20–72%, p = 0.004) against
viruses with I307, i.e., matched with the residue found at this site in
the vaccine (Fig. 3, upper left and Table S2); there was no signiﬁcant
vaccine effect with viruses that were mismatched at position 307,
i.e., I307X (VE=0%, p= 0.99, Fig. 3, upper right and Table S2); this cor-
responds to a typical sieve effect. In contrast, site 317 showed an atypical
sieve effect with a VE of 85% (CI: 32–97%, p = 0.004) against viruses
with mutations at site 317 (F317X) (Fig. 3, lower right and Table S2);
therewas no signiﬁcant VE for viruses that werematched to the vaccine
at site 317 (F317) (VE = 23%, p = 0.21, Fig. 3 lower left and Table S2).
In addition, we analyzed differential VE for these two sites by
comparing hazard ratios for one genotype vs. another (Table S3). We
found that the vaccine resulted in a ﬁve-fold reduction in infections by
viruses carrying F317X compared to infections with viruses with F317
(p = 0.040); there was a borderline signiﬁcant two-fold reduction
for viruses with I307X vs. I307 (p = 0.065). When viruses presenting
both I307X and F317 were compared to all other genotypes, the vaccine
decreased the rate of infection 3.56-fold against all other viruses (p =
0.003) (Table S3).
3.3. Effect of 307 Substitutions on Serum Reactivity
Recently, peptide microarray studies of plasma from RV144 vaccine
recipients identiﬁed the crown of the V3 loop (304RTSINI..GPGQVFYRT320)
as a highly immunogenic region and showed that when vaccine recipi-
ents had lowgp120-speciﬁc plasma IgA, high responses to this linear pep-
tide were associated with a decreased risk of HIV infection (OR = 0.49,
p = 0.007) (Gottardo et al., 2013). Furthermore, while neutralization by
vaccinees' specimens was weak, demonstrable neutralizing activity was
due primarily to V3-speciﬁc Abs (Monteﬁori et al., 2012). To determine
if the V3 sieve analysis and these previous studies were consistent withFig. 3. Estimated cumulative incidences of HIV-1 infection in placebo and vaccine recipients. The
whose viruses contained residues at V3 positions 307 (upper panels) or 317 (lower panels) w
panels) to the residues at these positions in the vaccine. The x-axis shows months since entrythe immunochemical characteristics of V3 Abs in vaccinees' plasma, spec-
imens from the plasma set described in the Materials and Methods sec-
tion were analyzed for their relative reactivities with cV3s carrying
substitutions at position 307 (Table 1), a primary contact residue for high-
ly cross-reactive V3 Abs (Almond et al., 2010; Jiang et al., 2010). It has
been shown that human V3 Ab responses preferentially use the VH5-51
germline gene and that these V3 Abs bind the N-terminal side of the V3
crown, with I307 as a key contact residue (Gorny et al., 2009).
When plasma reactivity tested by ELISA was compared between
wild type (WT) cV3B(BaL) and variants where I307was replacedwith res-
idues foundmore frequently in vaccinees' breakthrough viruses than in
placebo recipients (I307V, I307T, I307M, and I307A), Ab reactivity with
the variants was signiﬁcantly lower (p b 0.001 by paired t-test for each
variant compared to WT cV3B(BaL)) (Fig. 4, upper panel). Similarly, when
I307 was replaced in cV3AE(244) with the same four substitutions, plasma
reactivity was again signiﬁcantly lower in all cases (p b 0.0001) (Fig. 4,
lower panel). The data suggest that RV144-induced V3 Abs recognize an
epitope that includes I307, supporting the sieve analysis showing that
there was a decrease in the proportion of breakthrough viruses in vacci-
nees carrying I307.3.4. Consequences of Substitutions at Position 317 on Virus Function
Sieve analysis also showed that F317was retained in a greater propor-
tion of infecting breakthrough viruses in vaccinees (Fig. 2B). Notably,
F317 is known to often form part of the hydrophobic core of V3 that con-
tributes to the conformation of V3 but has little or no direct contactwith
V3 human monoclonal Abs (Stanﬁeld et al., 2004, 2006; Burke et al.,
2009; Jiang et al., 2010), thus obviating binding experiments with
F317X V3 peptides variants. However, structural data suggested an ex-
planation for the conservation of F317 in viruses infecting vaccinees:
F317 could play a structural role affecting virus ﬁtness, similar to the
role played by the V2 residue I181 (Spurrier et al., 2014). We therefore
investigated the frequency and nature of mutations at position 317
and the effect that substitutions at this site could have on infectivity.
Phenylalanine is present at position 317 in 5263/6010 (88%) viruses
from multiple subtypes and CRFs that were previously analyzed
(Almond et al., 2010). Only two vaccinees carried breakthrough viruses
with F317X; the V3 sequences of these viruses are shown in Table 3, re-
vealing that these viruses had ﬁve and six mutations in V3 whenprobability of acquiring HIV infection (y-axis) is shown for vaccine and placebo recipients
hich were either matched (I307 or F317; left panels) or mismatched (I307X or F317X; right
into the study.
Table 3
V3 sequences of gp120 immunogens and from the F317X breakthrough viruses found in
two vaccine recipients.a
Virus Sequence
A244
MN
AA062
AA090
a V3 sequences with HxB2 numbering according to (Ratner et al., 1987). Underlined res-
idues represent positions 307 and 317. Amino acids designated in blue differ from A244; red
differ fromMN; green differ from both the A244 and MN boosting protein immunogens.
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culating CRF01_AE viruses (Table 4).
To determine if substitutions at F317 affect infectivity, an F317L or an
F317W mutation was made in CM244 and 92TH023. These are muta-
tions that occur at F317 in the two F317X escape viruses in vaccinees
(see Fig. 2B). For both CRF01_AE strains tested, substitution of F317
with leucine reduced infectivity by ~65–85%, and substitution at this
site with tryptophan rendered both pseudoviruses non-infectious
(Fig. 5). An F317A mutant of 92TH023, bearing another substitution
that is rare but occurs at this site in nature, was also non-infectious
(D. Monteﬁori, personal communication).
Taken together, the immunologic and genetic data suggest that
vaccine-induced anti-V3 Abs exerted immune pressure on viruses bear-
ing I307, decreasing the number of infections by viruses carrying the
same I307 residue that RV144 V3 Abs can target (Fig. 2A). In contrast,
the increased proportion of vaccine breakthrough viruses with F317
(Fig. 2B) suggests a non-immunologic mechanism for selection for vi-
ruses bearing F317. This selection is based on both structural and func-
tional parameters, i.e., virus selection in the presence of Abs induced
by the RV144 vaccine appears to be related to both the packing of the
hydrophobic core of V3which includes I307, I309 and F317 and the impact
of the structure of the hydrophobic core on the accessibility of themost
immunogenic V3 epitope (which includes I307) (Jiang et al., 2010; Xiang
et al., 2010).
3.5. Structural Analysis of the V3 Hydrophobic Core
V3 structures in complex with mAbs 447-52D (PDB ID 4M1D) and
2557 (PDB ID 3LMR) show that the V3 hydrophobic core can occur on
either side of the V3 crown (Fig. 6, Jiang et al., 2010; Killikelly et al.,
2013). For the amino acids identiﬁed in the sieve analysis at position
317 (Phe, Leu, Trp, Tyr, and Ile, Fig. 2B), all side chains of the V3 crown
were energy-minimized by aMonte Carlo procedure using the ICM soft-
ware package (Abagyan et al., 1997). The V3 hydrophobic core com-
posed of residues 307, 309 and 317 was then analyzed for their side
chain contact areas. In the 447-52D bound conformation, the residue
317 side chain contact areas in the core were calculated to be 12.4 Å2,Fig. 4. Reactivity of plasma from RV144 vaccinees (week 26) with wild type cyclic V3
peptides from clade B (strain BaL: upper panel) and clade AE (strain A244: lower panel)
compared to variants with amino acid substitutions at position 307. All cyclic V3 peptides
were tested in two to three experiments,with two replicates in each experiment. Asterisks
denote p b 0.0001 by paired t-test.6.2 Å2, 16.8 Å2, 12.4 Å2, and 0.9 Å2, for amino acids Phe, Leu, Trp, Tyr,
and Ile, respectively. Similarly for the case of mAb 2557 V3-bound con-
formation, the calculated side chain contact areas were 16.0 Å2, 2.9 Å2,
22.6 Å2, 17.1 Å2, 12.9 Å2, respectively. The results show that F317 pro-
vides the best measure for formation of the hydrophobic core in terms
of side chain contact areas and hydrophobicity, except in the case of
Trp. The bulky side chain of a Trp residuemay be suboptimal for packing
against V1V2 in the trimer (Lyumkis et al., 2013), and as noted above,
the F317W mutation abrogates infectivity (Fig. 5). Notably, the two
F317X breakthrough viruses in vaccinees (with W317 or L317) displayed
rare mutations in the crown of V3 (Table 3) suggesting that for survival,
viruses with F317X require extensive V3 mutations to simultaneously
infect and escape Ab pressure. It is noteworthy that both of these two
X317 vaccine breakthrough viruses retained the I307 residue. Moreover,
in the just published 3.5 Å resolution structure of BG505 SOSIP.664
(Pancera, Zhou et al. 2014), the hydrophobic core of V3 has exactly
the same conformation as that recognized by V3 mAb 2557, and it
packs under several hydrophobic residues of V2. Thus the computation-
al analysis reported above based on the 2557-boundV3 structure is con-
sistent with the SOSIP conformation. Interestingly, V3 mAb 447-52D
was shown to be able to bind the BG505 SOSIP.664 trimer (Pancera
et al. 2014). This indicates that V3 can swing out from under V2, even
in the stabilized SOSIP, and, in addition, the V3 hydrophobic core can
ﬂip from the conformation recognized by mAb 2557 to that recognized
by mAb 447-52D (Fig. 6).
4. Discussion
The RV144 clinical trial showed an estimated VE of 31.2%, and that
V2-directed IgG Abs were found to be a signiﬁcant inverse correlate of
infection risk. Recently it was suggested that Abs reactive with a linear
V3 peptide from CRF01_AE also inversely correlated with infection
risk in vaccinees who had low levels of Env-speciﬁc plasma IgA, ADCC
and neutralizing Abs (Gottardo et al., 2013). Here we show thatTable 4
Comparison of amino acids in the boosting protein immunogens and those found in F317X
breakthrough viruses from vaccinees.
Position
#
Amino acid in
boosting
immunogens
Breakthrough
virus
designation
Amino acid mutation
in breakthrough
virusa
Frequencyb
309 I AA062 M 12.3%
317 F AA062 L 4.0%
318 Y AA062 F 2.8%
324 K&I AA062 T 0.4%
300 N&S AA090 F 10.5%
306 S&R AA090 G 7.9%
313 P AA090 Q 1.6%
315 R&Q AA090 H 4.0%
317 F AA090 W 2.4%
324 K&I AA090 V 0%
a Refers to mutations shown in green in Table 3.
b Frequency is based on a curated dataset of CRF01_AE Env sequences derived from
LANL (September, 2013) from which were removed those sequences that had out-of-
frame mutations, stop codons, or were hypermutated.
WT F317L F317W
0
100000
200000
300000
400000
CM244
RL
U
WT F317L F317W
0
50000
100000
150000
200000
92TH023
Fig. 5. Infectivity of wild type (WT) CM244 and 92TH023 pseudoviruses and pseudoviruses with an F317L mutation or an F317Wmutation.
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analysis suggests that breakthrough viruses differed between the
vaccine and placebo groups at V3 positions 307 and 317. These analyses
were supported by immunochemical studies showing RV144 plasma
Abs were less reactive with cyclic V3 variants of HIVB(BaL) and HIVAE(A244)
carrying substitutions for I307, and by virologic studies showing that sub-
stitutions at F317 decreased viral infectivity. Moreover, bioinformatics and
structural analyses suggest that F317 is strongly favored at this position
and appears to be optimal for the formation of the V3 hydrophobic core
which is essential for maintaining the correct conformation of the V3
loop (Jiang et al., 2010). Taken together, the data suggest that vaccine-
induced Abs that target I307 provided immune pressure and that, in the
presence of vaccine-induced Abs, retention of F317 may confer an advan-
tage to the virus, resulting in a VE of 85% against viruses with mutations
at position 317 in V3.
The immunologic data demonstrate the broad cross-reactivity of
vaccine-induced V3 Abs (Fig. 1 and Table 2) and recapitulate studies
documenting the ability of many V3 mAbs to cross-react immunologi-
cally with diverse V3 peptides (Gorny et al., 1997), to capture virions
from multiple subtypes (Nyambi et al., 2000), and to mediate cross-
clade neutralization, though V3mAbs preferentially neutralize sensitive
Tier 1 viruses (Gorny et al., 1992; Conley et al., 1994; Corti et al., 2010;
Hioe et al., 2010; Mouquet et al., 2011). Extensive structural data have
demonstrated that glycan-independent human V3 mAbs target the
mid-region (or “crown”) of the V3 loop (Stanﬁeld et al., 2004; BurkeFig. 6. Structure of the V3 hydrophobic core. The side chains of V3 residues I307, I309, and
F317 often pack against each other to form a hydrophobic core and are spatially located
at either side of the hairpin turn in the V3 crown as represented by the V3 structures in
complex with V3-speciﬁc mAb 447-52D (A) (Killikelly et al., 2013) or mAb 2557
(B) (Jiang et al., 2010). The V3 hairpin is drawn as a ribbon, and the side chains (toward
the reader) of I307, I309 and F317 as sticks and CPK spheres.et al., 2009; Gorny et al., 2009; Jiang et al., 2010). Sites 307 and 317 in
the crown are both part of the hydrophobic core of the V3 epitope rec-
ognized by these mAbs. These residues are highly conserved, with I307
and F317 each present in eight of nine HIV subtype consensus sequences
(Lynch et al., 2009), butwhereas position 307 is amajor contact residue,
position 317 has minor or no contact with most V3-speciﬁc human
mAbs (Stanﬁeld et al., 2004, 2006; Burke et al., 2009; Jiang et al., 2010).
This extensive body of literature is augmented by studies of two
mAbs, CH22 and CH23, which were isolated from vaccinees in the
RV135 trial who received a vaccine regimen identical to that of RV144
(Monteﬁori et al., 2012). The epitopes recognized by these two mAbs
are glycan-independent and react with V3 linear peptides in the
crown of the V3 loop containing I307 and F317 (shown in bold and
underlined: RKRIHIGPGRAFYTT and NTRTSINIGPGQVFY, respectively).
Notably, these are not highly mutated Abs, having VH mutation
frequencies of 3.7% and 4.5%, respectively, and each has a CDR H3 of
11 amino acids, characteristics similar to those found commonly in
human Abs (Tiller et al., 2007). CH22 administered to macaques was
able to protect against infectionwith SHIV BaL P4 (Haynes BF and Santra
S, personal communication), extending similar work reported earlier
(Watkins et al., 2011) and providing newdata on the breadth of reactiv-
ity and the protective effects of V3 Abs. These data add support for the
hypothesis that vaccine-induced V3-speciﬁc (and/or V2 speciﬁc) Abs
contributed to the reduction in infection rate in vaccinees. While it is
known that V3 Abs are induced early after infection and can drive
rapid viral escape (Tomaras et al., 2008), the fact that the sieve analysis
showed a difference between breakthrough viruses of vaccine and pla-
cebo recipients suggests that the V3 Abs exerted immune pressure in
the vaccinees and therefore the vaccine-induced Abs had a biologic ef-
fect on the viruses that emerged in the setting of human infection.
The results of the RV144 study, identifying inverse correlates of risk
related to levels of both V2 and V3 Abs (Haynes et al., 2012; Gottardo
et al., 2013) recapitulate some of the many V2 and V3 commonalities.
First, both crystallographic and cryo-EM studies of gp120 have shown
that V2 and V3 are closely packed together at the apex of the envelope
trimer (Bartesaghi et al., 2013; Julien et al., 2013; Lyumkis et al.,
2013). Both V2 and V3 induce highly cross-reactive Abs in HIV-
infected individuals (Gorny et al., 1997, 2012); and V2 and V3 induce
both glycan-independent (Gorny et al., 1997, 2002) and glycan-
dependent Abs (Pejchal et al., 2011). Most striking, perhaps, are the
similarities revealed by the RV144 sieve analyses of V2, published earli-
er (Rolland et al., 2012), and the sieve analysis related to V3, described
above. These studies suggest, independently, that immune pressure is
exerted on viruses that match the vaccine at V2 position 169 and also
at V3 position 307 (Fig. 2A). Vaccine efﬁcacy for viruses matched with
the vaccine at 169 is 48% (p = 0.004); VE for viruses matched with
the vaccine at 307 is 52% (p = 0.004). The analogy continues to hold
from the sieve analyses of site 181 in V2 and site 317 in V3 (Fig. 2B).
For these latter positions, there was an atypical sieve effect with a VE
of 78% (p = 0.003) against viruses with mutations at V2 site 181
(I181X), and a VE of 85% (p = 0.004) against viruses with mutations
at V3 site 317 (F317X).
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viral data suggest that both positions 169 (V2) and 307 (V3) are subject
to immune pressure by RV144-induced Abs that target 169 (Liao et al.,
2013; Zolla-Pazner et al., 2013) and 307 (XP Kong, personal communi-
cation and Monteﬁori et al., 2012). In contrast, the amino acid at 181 is
either a poor or non-contact residue for RV144-induced V2-speciﬁc
mAbs CH58 and CH59 or for mAbs that target the conformational
“V2i” epitope (Liao et al., 2013; Mayr et al., 2013; Spurrier et al.,
2014), and the amino acid at position 317 is a minor or non-contact res-
idue for V3 mAbs (Stanﬁeld et al., 2004; Burke et al., 2009; Jiang et al.,
2010). The conservation of V2 site 181 and V3 site 317 and their prefer-
ential presence in vaccine breakthrough viruses leads to the hypothesis
that these residues are not subject to direct immune pressure but in-
stead, in the presence of the vaccine-induced Abs, must be retained in
order to preserve the optimal structures of V2 and V3 that permit efﬁ-
cient infection (Jiang et al., 2010; Spurrier et al., 2014). It is noteworthy
however, that statistical signiﬁcance was not achieved for covariation
between positions 307 and 317 within either the vaccine or placebo
groups. In the vaccine group, 38 of 43 subjects were matched to both
181 and 317, and one subject was mismatched to both. In the placebo
group, 40 of 65 subjects were matched to both 181 and 317, and 6
were mismatched to both (one placebo recipient subject was excluded
for this analysis because of a sequencing artifact at site 317) (see
Table S4).
The data relevant to immune pressure exerted by the immune re-
sponse to the RV144 vaccine regimen have important implications for
the design of an effective HIV vaccine. A 31% reduction in infection
rate was achieved in RV144. The data support the hypothesis that
broadly cross-clade reactive V3 and V2 Abs (Fig. 1 and Zolla-Pazner
et al., 2014) played an important role in reducing the infection rate
despite the fact that the vaccine-induced Abs display modest muta-
tion rates from germline, i.e., b5%, and none of the mAbs isolated to
date from RV135 or RV144 vaccinees possess long CDR H3 regions
(Monteﬁori et al., 2012; Liao et al., 2013). Similarly, Abs mediating
ADCC also displayed modest levels of VH somatic mutation (0.5 to
1.5%) and showed considerable cross-clade activity (Bonsignori
et al., 2012).
Although there was poor neutralizing Ab activity demonstrated in
RV144 plasma (Monteﬁori et al., 2012), this must be interpreted cau-
tiously since negative data in vitro do not prove that virus neutralization
is not occurring in vivo. Thus, while a vaccine that reduces infection risk
by only 31% surely needs improvement, the data available from RV144
suggest that vaccine-induced conventional Abs, i.e., those with modest
rates of mutations in germline (b5% VH mutation rates) (Monteﬁori
et al., 2012; Liao et al., 2013) and without abnormally long CDR H3 re-
gions or other structural anomalies, if targeted to the correct epitopes
and present at appropriate levels over months to years should be effec-
tive (Zolla-Pazner, 2014). While desirable, broadly neutralizing, potent
Abs that carry long CDR H3 regions and display extreme mutation
rates from germline (as reviewed in Mascola and Haynes, 2013) have
not yet been induced by any immunization regimen and, as demon-
strated by RV144, are not necessarily needed to reduce infection risk.
Therefore, the results of RV144 support a targeted effort to improve
the design of immunogens such as those used in RV144, as well as re-
combinant epitope-scaffold immunogens to be used in prime-boost
regimens that will induce conventional Abs now shown to be correlates
of reduced risk of infection (Bonsignori et al., 2012; Haynes et al., 2012;
Gottardo et al., 2013; Zolla-Pazner et al., 2014).
5. Conclusions
This study provides important new information supporting a critical
role for vaccine-induced conventional antibodies in reducing the risk of
HIV infection. In addition to immune pressure exerted by V2-speciﬁc
antibodies, we show here that V3-speciﬁc antibodies also exerted im-
mune pressure on breakthrough viruses infecting vaccinees in theRV144 vaccine trial. The results reveal the similarities in immune pres-
sure exerted on the V2 and V3 regions of HIV-1 gp120 in vaccine recip-
ients. These data inform the process of designing more effective
candidate vaccines for reducing the rate of HIV infection.
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